维百奥(北京)生物科技有限公司

400-001-2615
info@vicbio.com
产品名称 Seraseq® FFPE HRD Negative RM(SeraCare)
目录号 0710-2644
别名 N/A
外观 N/A
分子量 N/A
CAS N/A
溶解度 N/A
存储条件 N/A
保存时间 N/A
备注1 N/A
备注2 N/A
目录号 规格 价格 库存状态  
0710-2644 1 x 10 µm 咨询客服 咨询客服

品名:Seraseq® FFPE HRD Negative RM

货号:0710-2644

品牌:SeraCare 


Product Specifications - FFPE HRD Negative RM 

GIs:31+2 

Number of genes:4(ATM,BRIP1,RAD51C,RAD51D) 

Number of variants:8(4 SNVs, 3 insertions, 1 deletion) 

Format:FFPE 

Size:1 x 10um curl 

DNA Yield*:>100 ng 


#Genomic Instability Score (GIS) calculated using Illumina TruSight™ Oncology (TSO) 500 HRD RUO assay which 

calculates a GIS using an algorithm licensed from Myriad Genetics. Illumina TSO 500 HRD is not available in Japan. 


*From 1x10 µm FFPE curl using QIAGEN QIAamp FFPE DNA Tissue Kit/Qubit DNA HS quant


Details

Genomic instability resulting from homologous recombination DNA repair deficiency (HRD) is a response biomarker 

to assess ovarian and breast cancer patient eligibility for PARP inhibitor and platinum-based therapies. HRD 

measurements have the potential to improve cancer therapy, however standardizing and democratizing HRD 

measurements remains challenging. LGC SeraCare has developed HRD reference materials to support the 

development, validation, and routine determination of HRD status in cancer patients. 


•Derived from tumor and matched-normal human cell lines 

•Blended to ~65% tumor content with SNP-matched normal cell lines 

•Additional biosynthetic single-nucleotide variants (SNVs) of 4 homologous recombination repair (HRR) genes 

•10 µm FFPE curl with DNA yield >100 ng per curl 

•Full-process FFPE format reference material validated by NGS and microarray assays with various HRD algorithms 

(see the Data Sheet for more details) 

•Manufactured in GMP-compliant, ISO 13485-certified facilities 


                                                        65ab095e3a4b3.png

维百奥生物代理SeraCare对照及参比物质。


维百奥(北京)生物科技有限公司,自2018年与SeraCare(现隶属于LGC Clinical Diagnostics)合作以来,长期为中国客户

提供包括SeraSeq系列参比物质,领域包括肿瘤、生殖健康遗传病。SeraCare研发和生产一系列临床参比物质,可以用于任何

研发阶段,以确保临床基因组学检测结果的准确性。

 

SeraCare参比物质涵盖的范围:

1)Next Generation Sequencing

2)Sanger Sequencing

3)Real-time PCR and digital PCR (dPCR)

4)Microarray

 

主要特点

1)Ready-to-use reference materials covering clinically-relevant variants and all variant types - SNVs, INDELS, CNVs, 

and RNA fusions

2)Highly multiplexed - provide significantly more data per NGS run, saving sequencing costs

3)Available in multiple formats to suite different workflow needs - purified DNA & RNA, ctDNA, encapsulated ctDNA 

in plasma, and FFPE

4)Manufactured in cGMP-compliant, ISO 13485-certified facilities

5)Stringent product release testing - all variants qualified by dPCR for allele frequencies or copy numbers

相关产品